Supreme Court ruled Bayer cannot be sued in state-court failure-to-warn cases
A Missouri judge approved Bayer’s agreement on Friday to pay as much as $7.25 billion over two decades to resolve thousands of claims from U.S. cancer patients. The allegations concern whether Bayer should have warned people that its popular Roundup weedkiller could cause lymphoma.
The legal theory at issue is failure to warn. The claims assert that Bayer should have told people that Roundup could cause lymphoma. Bayer, a Germany-based agrochemical maker, denies that Roundup causes cancer.
The nationwide settlement applies to Roundup users who are already ill and to Roundup users diagnosed with non-Hodgkin lymphoma in future years. Its future coverage gives the agreement a duration beyond the cases already pending at the time of approval.
Participants could receive average payments between $10,000 and $165,000. The amount depends on how they used Roundup, how old they were when diagnosed and the severity of their illness.
For Bayer, the settlement provides some financial certainty against mounting litigation costs. Those costs had led the company to contemplate pulling Roundup from U.S. agricultural markets.
Litigants also faced uncertainty while the settlement was pending. In June, the U.S. Supreme Court undercut one of the central arguments in the Roundup lawsuits. The high court ruled that Bayer cannot be sued in state courts on its failure-to-warn claims about cancer because federal regulations do not require a cancer warning label and states are forbidden from imposing additional labeling requirements.
Some attorneys for cancer patients contend that the settlement payouts are too small. Other attorneys argue that the deal is better than receiving nothing, which had become a heightened likelihood after the Supreme Court ruling.